Treace Medical Concepts, Inc. (TMCI) provided an update on its estimated financial performance for both the fourth quarter and the entire fiscal year of 2024 on Monday. The company's projected growth indicates an increase of approximately 10% for the fourth quarter and 12% for the full year when compared to the same periods in the previous year.
Treace Medical Concepts anticipates drawing in preliminary revenues ranging from $68.4 million to $68.8 million in the fourth quarter. For the full fiscal year 2024, the company estimates total revenues between $209 million and $209.4 million.
In comparison, analysts have on average forecasted that the company's revenue would reach $67.02 million for the fourth quarter and $207.58 million for the entire year of 2024.
In response to this financial outlook, Treace's stock is currently experiencing a surge, up by 12.64%, bringing it to $8.20 per share on the Nasdaq.
